The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China

2018 ◽  
Vol 59 (9) ◽  
pp. 2152-2158 ◽  
Author(s):  
Haigang Shao ◽  
Zhao Zeng ◽  
Jiannong Cen ◽  
Jun Zhang ◽  
Shuxiao Bai ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Children And Adolescents ◽  
Myeloid Leukemia ◽  
Molecular Response ◽  
Single Center ◽  
Single Center Study ◽  
The Impact ◽  
Center Study

Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back

2014 ◽  
Vol 55 (12) ◽  
pp. 2830-2834 ◽  
Author(s):  
Alaa Fadhil Alwan ◽  
Bassam F. Matti ◽  
Aladdin S. Naji ◽  
Abdulsalam H. Muhammed ◽  
Manal A. Abdulsahib
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Single Center ◽  
Phase Switching ◽  
Single Center Study ◽  
Center Study

Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study

2014 ◽  
Vol 56 (4) ◽  
pp. 882-886 ◽  
Author(s):  
Enaam Alsobhi ◽  
Mohammed Burhan Abrar ◽  
Mohammed Abdelaal ◽  
Ahmed Alsaeed ◽  
Ahmed Absi ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Adult Patients ◽  
Imatinib Therapy ◽  
Saudi Population ◽  
Single Center ◽  
Single Center Study ◽  
Center Study

scholarly journals The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Jarosław Dybko ◽  
Bożena Jaźwiec ◽  
Olga Haus ◽  
Donata Urbaniak-Kujda ◽  
Katarzyna Kapelko-Słowik ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Molecular Response ◽  
Single Center ◽  
Single Center Study ◽  
Significant Difference ◽  
Hasford Score ◽  
Tki Treatment ◽  
Eutos Score

The Sokal, Hasford, and EUTOS scores were established in different treatment eras of chronic myeloid leukemia (CML). None of them was reported to predict molecular response. In this single center study we tried to reevaluate the usefulness of three main scores in TKI era. The study group included 88 CML patients in first chronic phase treated initially with standard imatinib dose. All of them achieved major molecular response (MMR) in time points defined by European LeukemiaNet (ELN). 42 patients lost MMR in a median time of 47 months and we found a significant difference in MMR maintenance between intermediate-risk (IR) and low-risk (LR) patients assessed by Hasford score. All 42 patients were switched to second-generation TKI (2G-TKI) treatment. At 18 months of 2G-TKI therapy we have still found a significant difference in BCR-ABL transcript levels and MMR rate between IR and LR groups. We did not find any of the described differences discriminating patients by Sokal or EUTOS score. In this retrospective single center analysis we found Hasford score to be useful in predicting molecular response in first chronic phase of CML patients.

scholarly journals Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors

2021 ◽  
Vol 22 (15) ◽  
pp. 7806
Author(s):  
Maria Moschovi ◽  
Charikleia Kelaidi
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Children And Adolescents ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Hematopoietic Cell Transplantation ◽  
Adult Life ◽  
Normal Growth ◽  
Molecular Response ◽  
Treatment Paradigm ◽  
Treatment Free Remission

Chronic myeloid leukemia (CML) is a rare disease in children and adolescents. The goal of therapy in children and adolescents is normal life expectancy, without compromising normal growth and development and potential for achievement of milestones in adult life. The perspective of cure is also reflected in the goal of treatment-free remission, with its surrogate markers, such as deep molecular response, also becoming the new endpoints of therapy efficacy in children and adolescents. Chronic myeloid leukemia was a fatal disease to children and adolescents in the past. Following the treatment paradigm of imatinib, it became a chronic disease with the potential of complete remission and even cure without the long-term hazards of allogeneic hematopoietic cell transplantation. The diagnosis and treatment of CML affect a child’s trajectory through life and important physiological events like development and procreation.

Sign in / Sign up

Export Citation Format

Share Document